Kostas Alevizopoulos

Kostas Alevizopoulos is an accomplished leader in the biotech and pharmaceutical sectors, currently serving as the Chief Executive Officer of APIM Therapeutics since January 2020, where the focus is on developing the oncology drug candidate ATX-101. As a Partner at Ventac Partners since August 2007, Kostas has contributed to numerous technology-driven projects in biotech, pharma, and medtech. Additionally, Kostas serves as Chief Scientific Advisor at Gerolymatos International SA and as a Strategic Advisor for Exogenus Therapeutics. Previous roles include Chief Executive Officer at Medexis SA and Chief Scientific Officer at PNG Gerolymatos SA, among others. Kostas possesses a Ph.D. in Molecular Biology from the University of Lausanne and a Diploma in Biochemistry and Biology from Ethnikon kai Kapodistriakon Panepistimion Athinon.